Background {#Sec1}
==========

Even though surgery is the best curative option for solid tumours, surgical manipulation still carries a risk of tumour spreading. Even after complete removal, tumour cells released during surgery may eventually lead to recurrence if they escape immune surveillance \[[@CR1]--[@CR3]\]. It is well known that corticosteroids induce generalized immunosuppression \[[@CR4]\], and dexamethasone in particular can significantly suppress lymphokine production and cell proliferation \[[@CR4]\], impair natural killer function \[[@CR5], [@CR6]\], and promote resistance to apoptosis in tumour cells \[[@CR7]\].

However, many anaesthesiologists prefer to administer a single dose of dexamethasone because perioperative administration of this corticosteroid (4--10 mg intravenously) can reduce postoperative nausea/vomiting and surgical pain, and it can also enhance the quality of life during recovery, including the patient's emotional state and physical independence \[[@CR8], [@CR9]\]. Despite its widespread use, there have been few clinical studies evaluating the influence of perioperative dexamethasone on oncological outcomes with conflicting results.

Breast cancer is one of the most common malignancies in women and is a leading cause of death globally. Although many studies on the treatment of breast cancer and prevention of postoperative recurrence have been performed, the 10-year survival rate in Western Europe is still 70% \[[@CR10]\]. Therefore, it is necessary to investigate how dexamethasone, frequently used in the perioperative period, affects the outcomes of breast cancer, to address concerns about its immunosuppressive properties.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Our protocol was approved by the Institutional Review Board and Hospital Research Ethics Committee of Severance Hospital, Yonsei University Health System (4-2017-0677). The board waived the requirement for informed consents because this study was retrospective. The data were collected from the electronic medical documents of patients who underwent curative surgery of breast cancer at a tertiary single institution between November 2005 and December 2010. All data were analysed except those of patients who underwent multiple surgeries simultaneously, lacked anaesthesia or surgical information, or received steroid therapy for any reason.

Data collection {#Sec4}
---------------

Retrieved demographic data of the patients included age, sex, body mass index (BMI), co-morbidities, induction agents, anaesthetic agents, and antiemetic agents and analgesics. Dexamethasone was administered perioperatively at the discretion of the anaesthesiologists. We also collected surgical information including the surgical procedure and duration, expressed cellular receptors, tumour-node-metastasis (TNM) staging, tumour type, histological type, and any administered chemotherapy or radiotherapy. Clinicopathological parameters, including levels of oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER) 2, were obtained from the registry database. Tumours with ≥1% of their cells exhibiting ER and/or PR staining were considered positive for these receptors. In addition, we used the American Joint Committee on Cancer 7th edition criteria to identify the TNM staging \[[@CR11]\]. Local (or regional) metastasis was determined as tumour recurrence in the ipsilateral breast, regional lymph nodes, and/or chest wall. Every 6--12 months, the patients were observed clinically, which included taking a medical history, performing a physical examination, and performing laboratory and imaging tests to detect any cancer relapse. Any recurrence at a distant site, including the contralateral axillary or supraclavicular lymph nodes, was defined as a distant metastasis. Recurrence-free survival was calculated from the date of surgery to the date on which loco-regional or distant metastasis was first detected. The postoperative overall survival was assessed from the first date of curative surgery to the last follow-up date or death from any cause.

Statistical analyses {#Sec5}
--------------------

Patients who received dexamethasone and those who did not were compared using Student's t-test for continuous variables and the *X*^2^ test for categorical variables. *P*-values less than 0.05 were considered statistically significant. All potential confounders associated with recurrence and mortality after breast cancer surgery, which were chosen based on their clinical significance as reported in the literature were analysed using competing risk and Cox regression analyses, respectively. First, we performed univariate analysis to identify potential risk factors for postoperative recurrence and mortality; those with *P*-values of \< 0.1 were subjected to multivariate analysis, following which hazard ratios (HRs) and the associated 95% confidence intervals (CIs) were estimated. Fine and Gray competing risk analysis was performed for the recurrence with death as a competing risk. The univariate associations between dexamethasone usage and overall survival were assessed using Kaplan-Meier survival analysis together with the log-rank test. We also conducted a sensitivity test to assess the robustness of our findings with respect to the relationship between dexamethasone and each of recurrence and mortality, wherein we performed propensity score matching. Variables were adjusted to factors including BMI, hypertension, and diabetes mellitus, and the score was calculated with logistic regression. A greedy heuristic algorithm was used to identify the optimally matched groups without drop-outs; this excluded cases with differences exceeding twice the standard deviation (SD) during matching similar propensity scores. As a result, 1-to-5 matching was chosen because it carried the strongest statistical power. All statistical analyses were conducted with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) except for Kaplan-Meier curves, which were constructed using the R package version 3.0.2 (<http://www.r-project.org>).

Results {#Sec6}
=======

Subjects {#Sec7}
--------

We collected the data from 2729 patients who underwent surgery following their diagnosis with breast cancer during the study period. Among them, 63 patients who underwent multiple surgeries, 21 with unclear anaesthetic methods, and 17 who received preoperative steroid therapy were excluded. Ultimately, 2628 patients were analysed in our study. The patients were followed up to December 2015. The mean (SD) follow-up period for our study population was 70.1 (23.1) months.

Patients' demographic data {#Sec8}
--------------------------

A comparison of the characteristics of patients who received dexamethasone (*N* = 236) and those who did not (*N* = 2392) is shown in Table [1](#Tab1){ref-type="table"}. These two groups had similar baseline demographic data. However, there were significant differences with respect to anaesthetic agent, induction agent, nitric oxide use, antiemetic use, surgical procedure, and chemotherapy/radiotherapy administration between the two groups.Table 1Comparison of characteristics between patients who received dexamethasone and those who did notNon-dexamethasone\
(*N* = 2392)Dexamethasone\
(*N* = 236)*P*-valueDemographic data Age (years)50.1 ± 10.349.5 ± 9.30.418 BMI (kg m^−2^)23.3 ± 3.123.4 ± 3.10.764 Comorbidity  HTN473 (19.8)44 (18.6)0.732  DM172 (7.2)14 (5.9)0.594  Cardiac disease60 (2.5)4 (1.7)0.656  Pulmonary disease46 (1.9)6 (2.5)0.463  Endocrine disease109 (4.6)14 (5.9)0.332  Renal disease16 (0.7)1 (0.4)\> 0.999  Liver disease16 (0.7)2 (0.8)0.673  Neurological disease40 (1.7)4 (1.7)\> 0.999  Others14 (0.6)3 (1.3)0.191Anaesthetic factors Anaesthetic agent0.001  Volatiles   Sevoflurane1461 (61.1)141 (59.7)   Desflurane613 (25.6)47 (19.9)   Isoflurane242 (10.1)27 (11.4)   Enflurane31 (1.3)10 (4.2)  TIVA45 (1.9)11 (4.7) Induction agents0.029  Propofol1856 (77.6)168 (71.2)  Barbiturate536 (22.4)68 (28.8)N~2~O176 (7.4)28 (11.9)0.021Premedication^a^1585 (66.3)169 (71.6)0.111Antiemetic2069 (86.5)180 (76.3)\< 0.001Rescue analgesics2297 (96.0)225 (95.3)0.602Hypertensive events145 (6.1)15 (6.4)0.886Hypotensive events343 (14.3)25 (10.6)0.140Colloid administration36 (1.5)6 (2.5)0.267RBC transfusion12 (0.5)0 (0)0.616Surgical factors Surgical procedure0.014  BCS1156 (48.3)94 (39.8)  Mastectomy1218 (51.7)170 (60.2) Surgical duration (min)207.2 ± 131.0212.5 ± 108.50.487 TNM staging0.974  11126 (47.1)113 (47.9)  2876 (36.7)86 (36.4)  3387 (16.2)37 (15.7) Receptors  Oestrogen1652 (69.1)173 (73.3)0.183  Progesterone1506 (63.0)151 (64.0)0.778  HER2658 (27.5)60 (25.4)0.540 Histological analysis0.118  Well-differentiated508 (21.2)48 (20.3)  Moderately differentiated1058 (44.2)105 (44.5)  Poorly differentiated584 (24.4)48 (20.3)  Others242 (10.1)35 (14.8) Tumour types0.818  IDC2105 (88.0)212 (87.7)  ILC85 (3.6)10 (4.2)  Others202 (8.4)19 (8.1) Chemotherapy1619 (67.7)179 (75.8)0.010 Radiotherapy1559 (65.2)137 (58.1)0.032Data are presented as mean ± standard deviation, or number (percentage)*BMI* body mass index, *HTN* hypertension, *DM* diabetes mellitus, *TIVA* total intravenous anaesthesia, *N*~*2*~*O* nitrous oxide, *RBC* red blood cell, *BCS* breast conserving surgery, *TNM* tumour--node--metastasis, *HER2* human epidermal growth factor receptor 2, *IDC* invasive ductal carcinoma, *ILC* invasive lobular carcinoma^a^Premedication: Midazolam 0.03 mg kg^−1^ was administered

Risk factors for postoperative recurrence in breast cancer surgery {#Sec9}
------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} presents the factors that affected postoperative breast cancer recurrence as revealed by competing risk analyses. Multivariate analyses revealed that cancer recurrence was not associated with perioperative dexamethasone administration (hazard ratio \[HR\], 1.442; 95% confidence interval \[CI\], 0.969--2.145; *P* = 0.071). Table [3](#Tab3){ref-type="table"} details the propensity 1-to-5 matching analysis for our primary findings. This also showed no association between dexamethasone and postoperative recurrence (HR, 1.389; 95% CI, 0.904--2.132; *P* = 0.133). Other anaesthetic factors also were not correlated with the recurrence. The type of surgical procedure and higher TNM staging (stage 2 and 3) were significantly associated with breast cancer recurrence. Figure [1](#Fig1){ref-type="fig"}a shows the recurrence-free survival probabilities following breast cancer surgery according to dexamethasone administration; this showed no significant influence due to dexamethasone (*P* = 0.295).Table 2Competing risk analyses of factors associated with cancer recurrence after surgery for breast cancerVariablesUnivariateMultivariateHR95% CI*P*-valueHR95% CI*P*-valueDexamethasone No1 (ref)1 (ref) Yes1.3480.9121.9940.1341.4420.9692.1450.071Age0.9890.9761.0020.089Age (years) \< 401 (ref)1 (ref) 40--490.6730.4690.9670.0320.8660.5981.2540.447 50--590.7050.4821.0320.0720.7790.5261.1540.213 60--690.6650.4211.050.0800.7030.4161.1880.188 ≥700.5630.2541.2490.1580.5910.2471.4140.237BMI0.990.9481.0340.654BMI (kg m^−2^) \< 18.41.0330.5232.0390.9270.8350.4211.6580.607 18.4--22.91 (ref)1 (ref) 23--24.91.0260.7391.4230.8801.1000.7911.5300.572 25--29.91.0330.7491.4260.8421.0210.7381.4110.901 ≥300.730.2981.7890.4910.6260.2541.5460.310HTN No1 (ref)1 (ref) Yes0.9520.6861.3220.7701.0450.7141.5310.820DM No1 (ref)1 (ref) Yes1.1320.7001.8320.6121.1580.6811.9680.588Anaesthetic agents TIVA1 (ref)1 (ref) Volatile1.2470.5502.8300.5971.0720.4702.4410.869N~2~O No1 (ref) Yes1.3250.8791.9970.179Transfusion No1 (ref) Yes2.5910.64410.4260.180Premedication^a^ No1 (ref) Yes0.8780.6701.1500.345Surgical procedure BCS1 (ref)1 (ref) Mastectomy2.5161.8833.360\< 0.0011.9341.4292.618\< 0.001TNM staging 11 (ref)1 (ref) 22.3971.6743.431\< 0.0011.7781.1682.7060.007 37.3955.21710.48\< 0.0015.3003.4338.183\< 0.001Oestrogen receptor No1 (ref)1 (ref) Yes0.5760.4430.748\< 0.0010.8860.5971.3150.549Progesterone receptor No1 (ref)1 (ref) Yes0.6050.4670.783\< 0.0010.8350.5711.2220.355Chemotherapy No1 (ref)1 (ref) Yes3.2652.2134.818\< 0.0010.9580.5801.5820.866Radiotherapy No1 (ref) Yes1.2110.9171.5970.177*CI* confidence interval, *HR* hazard ratio, *BMI* body mass index, *HTN* hypertension, *DM* diabetes mellitus, *TIVA* total intravenous anaesthesia, *N*~*2*~*O* nitrous oxide, *BCS* breast conserving surgery, *TNM* tumour-node-metastasis^a^Premedication: Midazolam 0.03 mg kg^−1^ was administeredTable 3Factors associated with postoperative cancer recurrence in patients with breast cancer after propensity score matchingVariablesUnivariateMultivariateHR95% CI*P*-valueHR95% CI*P*-valueDexamethasone No1 (ref)1 (ref) Yes1.2510.8221.9030.2951.3890.9042.1320.133Age0.9820.9641.0000.055Age (years) \< 401 (ref)1 (ref) 40--490.7360.4661.1620.1881.0530.6551.6900.832 50--590.5720.3470.9440.0290.6140.3641.0370.068 60--690.6850.3611.3010.2480.6030.2891.2580.177 ≥700.6130.1862.0170.4210.4530.1261.6280.225BMI0.9770.9221.0350.436BMI (kg m^−2^) \< 18.41.3490.5423.3580.5201.4770.5853.7300.409 18.4--22.91 (ref)1 (ref) 23--24.91.1590.7651.7570.4851.3210.8662.0150.196 25--29.90.9190.5971.4170.7031.0320.6671.5970.888 ≥300.3260.0452.3530.2660.3450.0472.5240.295HTN No1 (ref)1 (ref) Yes1.1090.7181.7130.6421.2700.7612.1180.360DM No1 (ref)1 (ref) Yes1.4380.7552.7400.2691.5020.7423.0400.259Anaesthetic agents TIVA1 (ref)1 (ref) Volatile0.5750.2351.4060.2250.7820.3121.9600.600N~2~O No1 (ref) Yes1.5150.9192.4970.103Transfusion No1 (ref) Yes1.8940.26513.5470.525Premedication^a^ No1 (ref) Yes0.8730.6111.2490.458Surgical procedure BCS1 (ref)1 (ref) Mastectomy2.1191.4583.078\< 0.0011.6591.1212.4570.012TNM staging 11 (ref)1 (ref) 22.4541.5034.006\< 0.0012.1601.2233.8140.008 38.2155.12113.177\< 0.0017.7804.30314.064\< 0.001Oestrogen receptor No1 (ref)1 (ref) Yes0.5640.4000.7960.0010.7830.4631.3250.363Progesterone receptor No1 (ref)1 (ref) Yes0.5720.4070.8030.0010.8180.4911.3630.441Chemotherapy No1 (ref)1 (ref) Yes1.8701.2932.7060.0010.6690.3501.2790.224Radiotherapy No1 (ref) Yes1.6831.1392.4860.009*CI* confidence interval, *HR* hazard ratio, *BMI* body mass index, *HTN* hypertension, *DM* diabetes mellitus, *TIVA* total intravenous anaesthesia, *N*~*2*~*O* nitrous oxide, *BCS* breast conserving surgery, *TNM* tumour-node-metastasisIn 1 to 5 propensity matching process, the basic characteristics of 1224 subjects in the control group were considered to be different from the dexamethasone group and excluded from the final matching analyses. Consequently, 234 patients who received dexamethasone and 1170 patients who did not receive dexamethasone were included^a^Premedication: Midazolam 0.03 mg kg^−1^ was administeredFig. 1**a** Probability of recurrence-free survival following breast cancer surgery as a function of dexamethasone administration. **b** Probability of postoperative overall survival in breast cancer patients as a function of dexamethasone administration

Related-factors for postoperative mortality in breast cancer surgery {#Sec10}
--------------------------------------------------------------------

Table [4](#Tab4){ref-type="table"} presents the factors that potentially influence postoperative mortality in patients with breast cancer following Cox regression. Multivariate analyses revealed no association between perioperative dexamethasone administration and mortality (HR, 1.389; 95% CI, 0.904--2.132; *P* = 0.133). Instead, this was significantly associated with old age (≥70 years), transfusion, the type of surgical procedure, higher TNM staging (stage 3), and progesterone receptor-positive status. Table [5](#Tab5){ref-type="table"} details the association between dexamethasone and postoperative mortality as identified after the propensity 1-to-5 matching. While there was no association between dexamethasone and postoperative mortality (HR, 1.506; 95% CI, 0.886--2.561; *P* = 0.130), the type of surgical procedure, higher TNM stage (≥3), and progesterone receptor were significantly associated with postoperative mortality. Figure [1](#Fig1){ref-type="fig"}b shows the postoperative overall survival probability in patients according to dexamethasone use; this showed that dexamethasone did not significantly influence the overall survival (*P* = 0.442).Table 4Univariate and multivariate Cox regression analyses of factors associated with mortality after surgery for breast cancerVariablesUnivariateMultivariateHR95% CI*P*-valueHR95% CI*P*-valueDexamethasone No1 (ref)1 (ref) Yes1.0510.6521.6960.8371.2560.7702.0470.361Age1.0281.0131.042\< 0.001Age (years) \< 401 (ref)1 (ref) 40--490.5860.3690.9310.0240.7720.4801.2400.285 50--590.8520.5391.3460.4930.9220.5751.4790.736 60--691.1750.7161.9290.5231.1510.6542.0270.625 ≥702.7131.5344.798\< 0.0012.4271.2204.8300.012BMI0.9930.9471.0410.758BMI (kg m^−2^) \< 18.41.5640.8103.0210.1831.2710.6532.4740.480 18.4--22.91 (ref)1 (ref) 23--24.91.140.7881.6490.4881.1800.8131.7150.384 25--29.91.0160.6961.4830.9340.9630.6571.4130.847 ≥301.2090.5272.7750.6541.2650.5452.9390.584HTN No1 (ref)1 (ref) Yes1.5641.1282.1660.0071.0480.7031.5630.817DM No1 (ref)1 (ref) Yes1.8101.1482.8520.01071.2170.7322.0230.450Anaesthetic agents TIVA1 (ref)1 (ref) Volatile0.4970.1232.0170.3283.0360.73812.4850.124N~2~O No1 (ref) Yes1.3880.8922.1580.146Transfusion No1 (ref)1 (ref) Yes7.5272.79220.296\< 0.0015.5511.98015.5590.001Premedication^a^ No1 (ref) Yes0.8170.6021.1080.193Surgical procedure BCS1 (ref)1 (ref) Mastectomy3.0732.1694.355\< 0.0012.2441.5563.236\< 0.001TNM staging 1 21.9021.2752.8380.0021.5910.9942.5450.053 36.3124.3189.226\< 0.0015.4353.3388.850\< 0.001Oestrogen receptor No1 (ref)1 (ref) Yes0.3980.2970.533\< 0.0010.7580.4881.1770.217Progesterone receptor No1 (ref)1 (ref) Yes0.3690.2740.496\< 0.0010.5650.3670.8700.010Chemotherapy No1 (ref)1 (ref) Yes1.8701.2932.706\< 0.0010.6740.4031.1280.133Radiotherapy No1 (ref) Yes0.9220.6821.2460.597*CI* confidence interval, *HR* hazard ratio, *BMI* body mass index, *HTN* hypertension, *DM* diabetes mellitus, *TIVA* total intravenous anaesthesia, *N*~*2*~*O* nitrous oxide, *BCS* breast conserving surgery, *TNM* tumour-node-metastasis^a^Premedication: Midazolam 0.03 mg kg^−1^ was administeredTable 5Factors associated with postoperative mortality in patients with breast cancer after propensity score matchingVariablesUnivariateMultivariateHR95% CI*P*-valueHR95% CI*P*-valueDexamethasone No1 (ref)1 (ref) Yes1.2230.7332.0410.4421.5060.8862.5610.130Age1.0050.9831.0280.636Age (years) \< 401 (ref)1 (ref) 40--490.6070.3311.1130.1070.9790.5171.8550.949 50--590.7630.4161.4000.3820.7780.4111.4730.440 60--691.1650.5742.3640.6730.9620.4192.2080.927 ≥701.0870.3183.7140.8940.8660.2263.3230.834BMI0.9910.9251.0630.810BMI (kg m^−2^) \< 18.40.8520.5423.3580.5200.7590.1793.2160.709 18.4--22.91 (ref)1 (ref) 23--24.91.4490.7651.7570.4851.6470.9942.7300.053 25--29.91.0120.5971.4170.7031.0080.5841.7400.976 ≥30HTN No1 (ref) Yes1.6921.0522.7230.030DM No1 (ref) Yes1.7750.8583.6720.122Anaesthetic agents TIVA1 (ref)1 (ref) Volatile1.0500.2584.2720.9461.4000.3325.8920.647N~2~O No1 (ref) Yes1.5230.8402.7630.166Transfusion No1 (ref)1 (ref) Yes6.1131.50324.8570.0113.0630.690013.6000.141Premedication^a^ No1 (ref) Yes0.7960.5151.2310.305Surgical procedure BCS1 (ref)1 (ref) Mastectomy2.6991.6524.408\< 0.0012.2891.3673.8330.002TNM staging 11 (ref)1 (ref) 22.4031.2934.4660.0061.5530.7743.1170.216 38.5874.77015.458\< 0.0015.5092.73211.106\< 0.001Oestrogen receptor No1 (ref)1 (ref) Yes0.3380.2220.514\< 0.0010.6990.3741.3050.261Progesterone receptor No1 (ref)1 (ref) Yes0.2800.1800.435\< 0.0010.4280.2280.8030.008Chemotherapy No1 (ref)1 (ref) Yes4.6672.15610.103\< 0.0011.3810.5493.4740.493Radiotherapy No1 (ref) Yes1.4730.9262.3430.102*CI* confidence interval, *HR* hazard ratio, *BMI* body mass index, *HTN* hypertension, *DM* diabetes mellitus, *TIVA* total intravenous anaesthesia, *N*~*2*~*O* nitrous oxide, *BCS* breast conserving surgery, *TNM* tumour-node-metastasisIn 1 to 5 propensity matching process, the basic characteristics of 1224 subjects in the control group were considered to be different from the dexamethasone group and excluded from the final matching analyses. Consequently, 234 patients who received dexamethasone and 1170 patients who did not receive dexamethasone were included^a^Premedication: Midazolam 0.03 mg kg^−1^ was administered

Sub-group analyses for association between dexamethasone and subtypes of breast cancer {#Sec11}
--------------------------------------------------------------------------------------

In the sub-group analyses to specify association between dexamethasone and subtypes of breast cancer including ER-dependency, PR-dependency or TNM staging, there was no association between dexamethasone and the recurrence or mortality in ER-dependent breast cancer. Instead, dexamethasone was significantly associated with the risk of mortality in PR-positive breast cancer (HR 2.637, 95% CI 1.106--6.288, *p* = 0.029). Moreover, dexamethasone showed a significant tendency to increase risk of the recurrence in TNM stage 1of breast cancer (HR 2.976, 95% CI 1.106--6.288, *p* = 0.002).

Discussion {#Sec12}
==========

Dexamethasone is an effective and widely used agent that is administered perioperatively to improve the quality of recovery after surgery. However, dexamethasone can also induce immunosuppression and may cause tumour cells to escape from the immune system. As a patient's perioperative management is only handled by the anaesthesiologist, the choice of anaesthetic agent may critically affect post-surgical outcomes. Hence, anaesthesiologists should consider the possibility of immunosuppression before administering dexamethasone. From this perspective, investigating the effects of perioperative dexamethasone administration on postoperative oncologic outcomes, in patients who were already immunocompromised due to the perioperative environment, is very important. In our study, we found that perioperative dexamethasone was not associated with recurrence or mortality of patients after breast cancer surgery.

Stress response following surgery is part of the systemic reaction to an injury, and it encompasses a wide range of immunological, endocrinological, and haematological effects \[[@CR12]\]. Importantly, the inevitable immunosuppression during the perioperative period can allow tumour cells to evade the immune system, leading to recurrence in patients who are prone to undetectable micrometastases \[[@CR13]\], even though surgical resection of a tumour remains the optimal curative treatment. Previous investigations suggest that perioperative impairment of the immune system increases the risk of cancer recurrence in patients undergoing oncologic surgery \[[@CR14], [@CR15]\]. Glucocorticoids are involved in postoperative suppression of natural killer cell activity \[[@CR16]\]; their role in immunosuppression includes the significant suppression of lymphokine production and cell proliferation \[[@CR4]\], impairment of natural killer function \[[@CR6]\], and rendering tumour cells more resistant to apoptosis \[[@CR7]\]. Glucocorticoids are also known to induce proliferation in normal cells such as erythroid progenitor cells and fibroblasts \[[@CR17], [@CR18]\]; and previous studies have shown that low concentrations of dexamethasone also can induce in vitro proliferation of cancer cells such as those derived from glioma \[[@CR19]\], astrocytoma \[[@CR20]\], and Kaposi's sarcoma \[[@CR21]\]. Hence, even though dexamethasone-induced immunosuppression may be temporary, it can aggravate tumour cell evasion of immune surveillance.

The issue of perioperative dexamethasone-induced immunosuppression influencing oncological outcomes has recently been investigated by other groups. Yu and colleagues retrospectively studied 515 patients who underwent rectal cancer surgery and found a higher rate of cancer recurrence in patients who received dexamethasone \[[@CR22]\]. Moreover, patients receiving a single dose of dexamethasone before undergoing colon cancer surgery were shown to have a potentially increased risk of distant recurrence \[[@CR23]\]. On the other hand, a retrospective study of 309 women who underwent endometrial cancer surgery showed that dexamethasone that was administered to prevent postoperative nausea and vomiting was not associated with an increased risk of cancer recurrence or with altered progression-free or overall survival compared to patients who did not receive dexamethasone \[[@CR24]\]. Additionally, De Oliveira et al. \[[@CR25]\] demonstrated that perioperative dexamethasone had no effect on recurrence in patients diagnosed with ovarian cancer, although they did not report survival data. Another study found that perioperative dexamethasone might improve postoperative survival in human pancreatic adenocarcinoma \[[@CR26]\].

Our finding that perioperative dexamethasone appears to have no significant effect on postoperative outcomes including recurrence free and overall survival of patients who underwent breast cancer surgery may be explained as follows: Dexamethasone has been shown to reduce the perioperative stress response \[[@CR27], [@CR28]\]; therefore, the direct immunosuppression caused by dexamethasone may be counteracted by its protective effect on the normal stress response to surgical stimuli. Dexamethasone also has pro-apoptotic properties that may lengthen the survival of patients with certain types of cancer \[[@CR29], [@CR30]\]. Glucocorticoids can destroy cancerous lymphoid cells, and are thus essential for treating lymph node tissue malignancies.

In contrast to these favourable characteristics of dexamethasone, glucocorticoids in general may also induce the growth of malignant solid tumours and increase their dissemination as a consequence of decreasing inter-cell adhesiveness and enhancing tissue permeability. In this regard, two recent reports were published on the relationship between glucocorticoid use and breast cancer risk. They described no evidence of glucocorticoid use influencing breast cancer recurrence in Danish populations \[[@CR31], [@CR32]\]. However, these studies included breast cancer patients regardless of whether they underwent surgery, and also investigated various types of glucocorticoids combined. To the best of our knowledge, ours is the first study to investigate the impact of perioperative dexamethasone on postoperative recurrence and mortality in patients with breast cancer, and to determine whether single-dose dexamethasone is safe in patients undergoing breast cancer surgery.

Based on our findings, chemotherapy was not significantly associated with postoperative recurrence and mortality in the multivariate analyses, in contrast to univariate analysis results. This may be because of confounding effects associated with chemotherapy and TNM staging, as chemotherapy is administered according to the TNM stage in breast cancer patients. However, we could not avoid investigating chemotherapy and TNM stage together in our multivariate analysis model, as both were critical for determining the effect of dexamethasone on postoperative outcomes. Moreover, a higher TNM stage remained a critical risk factor for postoperative recurrence and mortality despite chemotherapy. Although the administration of dexamethasone to subjects with chemotherapy may lead to worsened prognoses in patients with breast cancer, it likely has little impact on the perioperative immunity of patients because surgery is usually scheduled 1 month after completing chemotherapy at our institution. Moreover, while the antiemetic regimen is prescribed according to the degree of nausea experienced by patients, dexamethasone is not a routinely administered agent. Furthermore, a large cohort study of breast cancer patients \[[@CR32]\] showed no evidence of an association between preoperative systemic, inhaled, or intestinal-acting glucocorticoids and breast cancer recurrence. As our study was designed to investigate the effect of a single dose of dexamethasone during anaesthesia on oncologic outcomes, we did not include the data of dexamethasone administered for neoadjuvant chemotherapy. Additionally, we performed sub-group analyses to find out more association between dexamethasone and subtypes of breast cancer such as ER-dependency, PR-dependency, or TNM staging. In this result, we found that dexamethasone is associated with the risk of mortality in PR-dependent breast cancer and recurrence in TNM stage 1 after breast cancer surgery. This detrimental effect of dexamethasone in TNM stage 1 and PR-dependent breast cancer requires further studies with sufficient sample size.

The present study is limited by its retrospective nature. Our patients were not randomised, and the clinical protocol was not standardised; therefore, selection bias and the effects of unmeasured confounding variables cannot be excluded. Moreover, the factors that influenced care providers to administer or forgo perioperative dexamethasone are unknown, although such decisions were unlikely to be associated with tumour status. Even though single-dose perioperative dexamethasone administration has known to have no association with an increased risk of acute postoperative complications including wound infection, the lack of information regarding dexamethasone-related adverse effects other than recurrence or mortality was considered a weak point of the study. There may be limited strength to the conclusion because of the relatively small population who received dexamethasone compared with the large total sample size. Nevertheless, the reliability of our data was buttressed by the retrospective design to some extent, because our homogeneous patients comprising 2628 women were managed perioperatively in a similar manner at the same hospital. Above all, our analyses may have the statistical power by the sensitivity test of 1-to-5 propensity score matching, which led to well-matched groups and minimized the potential for significant confounding. Although randomised clinical trials are required for definitive conclusions, our results from post-propensity score matching ought to add valuable insight despite the study's limitations.

Conclusions {#Sec13}
===========

In conclusion, our results suggest that a single dose of perioperative dexamethasone does not increase the risk of recurrence in patients after breast cancer surgery, and it appears to be safe in this patient population.
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